Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 2/20 | 0.38 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | OXTR | P30559 | 3/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.33 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.33 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.33 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23871517 | 0.99 | FAP (0.38) | FAPNAA50APLNRCALCRLMAPK8 | |
| SCHEMBL26391856 | 0.95 | APLNR (0.38) | FAPNAA50APLNRCALCRLMAPK8 | |
| SCHEMBL29308497 | 0.94 | FAP (0.36) | FAPNAA50APLNRCALCRLMAPK8 | |
| SCHEMBL29308274 | 0.93 | MAPK8 (0.34) | FAPNAA50APLNRCALCRLMAPK8 | |
| SCHEMBL22922802 | 0.92 | NAA50 (0.42) | NAA50APLNRCALCRLMAPK8MAPK9 | |
| SCHEMBL29308489 | 0.91 | NAA50 (0.39) | FAPNAA50APLNRCALCRLMAPK8 | |
| SCHEMBL29308708 | 0.91 | PREP (0.37) | FAPCALCRLTERT | |
| SCHEMBL29308258 | 0.90 | CTSD (0.34) | FAPNAA50APLNRMAPK8MAPK9 | |
| SCHEMBL26388157 | 0.90 | FAP (0.36) | FAPNAA50APLNRKEAP1OXTR | |
| SCHEMBL29308229 | 0.90 | CTSD (0.37) | NAA50APLNRCALCRLMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-20230312648-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | YUYU PHARMA, INC. (KR) | 2023-10-05 | — | — | US | disclosed |
| WO-2021191689-A2 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | YUYU PHARMA, INC. (KR) | 2021-09-30 | — | — | WO | disclosed |
| WO-2020099925-A2 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | YUYU PHARMA, INC. (KR) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312648-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | VIP, IAPP, SCTR | FAP 1121/4885NAA50 3702/4885APLNR 85/4885 |
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | VIP, IAPP, NGLY1 | FAP 530/4885NAA50 4530/4885APLNR 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.